Literature DB >> 19811899

Serum KL-6 in fibrotic NSIP: Correlations with physiologic and radiologic parameters.

Koji Sakamoto1, Hiroyuki Taniguchi, Yasuhiro Kondoh, Takeshi Johkoh, Hiromitsu Sumikawa, Tomoki Kimura, Osamu Nishiyama, Keisuke Kato, Kensuke Kataoka, Kenzo Ono, Mansanori Kitaichi, Yoshinori Hasegawa.   

Abstract

BACKGROUNDS: Fibrotic nonspecific interstitial pneumonia (f-NSIP) has been recognized as a distinct disease entity. KL-6 has been reported to be a useful serum marker in interstitial lung diseases. However, few previous reports evaluated the value of serum KL-6 exclusively in f-NSIP, as distinct from other subtypes of idiopathic interstitial pneumonia, therefore the associations of serum KL-6 with clinical and radiologic findings in this population remain unclear.
METHODS: Serum KL-6 levels were measured in twenty-six consecutive patients with f-NSIP diagnosed by surgical lung biopsy. Pulmonary function testing, bronchoalveolar lavage, subjective measurement of dyspnea using baseline dyspnea index (BDI), and HRCT were performed in parallel. Two radiologists conducted independent visual examinations of the pattern and extent of abnormalities on HRCT.
RESULTS: Serum KL-6 levels were elevated above the cut-off level in all patients. In univariate analysis serum KL-6 levels showed negative correlations with BDI (rho=-0.52; p<0.01). Serum KL-6 had positive correlations with the extent of several patterns of opacities (rho=0.56-0.62; p<0.01). Among them, only the extent of traction bronchiectasis in HRCT showed significant association with serum KL-6 in multivariate analysis (beta-coefficient=0.043; p<0.01).
CONCLUSIONS: Serum levels of KL-6 were elevated in f-NSIP, and were correlated with the extent of fibrotic abnormalities on HRCT, suggesting a value of serum KL-6 as a marker for fibrosis in f-NSIP. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19811899     DOI: 10.1016/j.rmed.2009.08.011

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  17 in total

1.  Acute exacerbation of idiopathic pulmonary fibrosis: high-resolution CT scores predict mortality.

Authors:  Kiminori Fujimoto; Hiroyuki Taniguchi; Takeshi Johkoh; Yasuhiro Kondoh; Kazuya Ichikado; Hiromitsu Sumikawa; Takashi Ogura; Kensuke Kataoka; Takahiro Endo; Atsushi Kawaguchi; Nestor L Müller
Journal:  Eur Radiol       Date:  2011-08-07       Impact factor: 5.315

2.  Serum KL-6 and surfactant protein-D as monitoring and predictive markers of interstitial lung disease in patients with systemic sclerosis and mixed connective tissue disease.

Authors:  Hideaki Yamakawa; Eri Hagiwara; Hideya Kitamura; Yumie Yamanaka; Satoshi Ikeda; Akimasa Sekine; Tomohisa Baba; Koji Okudela; Tae Iwasawa; Tamiko Takemura; Kazuyoshi Kuwano; Takashi Ogura
Journal:  J Thorac Dis       Date:  2017-02       Impact factor: 2.895

3.  Answer to the Letter to the Editor of Jie Weng et al. concerning, "Relationship between preoperative serum rapid turnover proteins and early-stage surgical wound infection after spine surgery" by D. Kudo et al. (Eur Spine J; 2016: doi:10.1007/s00586-016-4855-z).

Authors:  Daisuke Kudo; Naohisa Miyakoshi; Michio Hongo; Yuji Kasukawa; Yoshinori Ishikawa; Takashi Mizutani; Yoichi Shimada
Journal:  Eur Spine J       Date:  2018-03-26       Impact factor: 3.134

4.  KL-6 as a Biomarker of Interstitial Lung Disease Development in Patients with Sjögren Syndrome: A Retrospective Case-Control Study.

Authors:  Yu-Hsiang Chiu; Chen-Chih Chu; Chun-Chi Lu; Feng-Cheng Liu; Shin-En Tang; Shi-Jye Chu; San-Yuan Kuo; Hsiang-Cheng Chen
Journal:  J Inflamm Res       Date:  2022-04-08

5.  Diagnostic value of KL-6 in idiopathic interstitial pneumonia.

Authors:  Peiyan Zheng; Xiaoqing Liu; Huimin Huang; Zijun Guo; Ge Wu; Haisheng Hu; Chuanxu Cai; Wenting Luo; Nili Wei; Qian Han; Baoqing Sun
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

6.  Effects of molecular structural variants on serum Krebs von den Lungen-6 levels in sarcoidosis.

Authors:  Masahiko Shigemura; Yasuyuki Nasuhara; Satoshi Konno; Chikara Shimizu; Kazuhiko Matsuno; Etsuro Yamguchi; Masaharu Nishimura
Journal:  J Transl Med       Date:  2012-07-11       Impact factor: 5.531

7.  The Diagnostic Value of the Interstitial Biomarkers KL-6 and SP-D for the Degree of Fibrosis in Combined Pulmonary Fibrosis and Emphysema.

Authors:  Shigeki Chiba; Hiromitsu Ohta; Kyoko Abe; Shu Hisata; Shinya Ohkouchi; Yasushi Hoshikawa; Takashi Kondo; Masahito Ebina
Journal:  Pulm Med       Date:  2012-02-28

8.  Circulating thymus and activation-regulated chemokine/CC chemokine ligand 17 is a strong candidate diagnostic marker for interstitial lung disease in patients with malignant tumors: a result from a pilot study.

Authors:  Hiromichi Yamane; Nobuaki Ochi; Tomoko Yamagishi; Yoshihiro Honda; Masami Takeyama; Nagio Takigawa
Journal:  Ther Clin Risk Manag       Date:  2015-06-17       Impact factor: 2.423

9.  Interstitial lung disease in clinically amyopathic dermatomyositis with and without anti-MDA-5 antibody: to lump or split?

Authors:  Satoshi Ikeda; Machiko Arita; Mitsunori Morita; Satoshi Ikeo; Akihiro Ito; Fumiaki Tokioka; Maki Noyama; Kenta Misaki; Kenji Notohara; Tadashi Ishida
Journal:  BMC Pulm Med       Date:  2015-12-09       Impact factor: 3.317

Review 10.  Molecular biomarkers in interstitial lung diseases.

Authors:  Angelo De Lauretis; Elisabetta A Renzoni
Journal:  Mol Diagn Ther       Date:  2014-10       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.